A method of recovering a lithium salt from a lithium battery waste mass, comprising the steps of: (a) dissolving the lithium sail in the lithium battery waste mass in a weight of water equivalent to 100 to 0.1 times the weight of the lithium battery waste mass, either in a one-off treatment or successive treatments; (b) evaporating the aqueous solution to dryness; and (c) working up the dry residue with a solvent comprising water, a carbonate, or mixtures thereof.
Use of a compound of Formula 1 in a non-aqueous battery electrolyte formulation: wherein: R is an optionally fluorinated alky group, conveniently C1-6; each Y is independently H or F. X is H; a halogen, conveniently F; or an alkyl or a fluoroalkyl, conveniently C1-6; each Z is independently a halogen, conveniently F; or H.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 10/0567 - Liquid materials characterised by the additives
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 10/0569 - Liquid materials characterised by the solvents
H01G 11/60 - Liquid electrolytes characterised by the solvent
H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
H01G 11/64 - Liquid electrolytes characterised by additives
C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
C07C 255/16 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
A coolant for cooling an electrical / electronic element by direct immersion cooling, comprising a partially fluorinated ether with the structure (of compound 1) wherein R1, R2, R3, R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl and R5 is independently selected from the group CF3, alkyl, fluoroalkyl, perfluoroalkyl, haloalkyl perfluorohaloalkyl.
H01M 10/6568 - Liquids characterised by flow circuits, e.g. loops, located externally to the cells or cell casings
H01M 10/6569 - Fluids undergoing a liquid-gas phase change or transition, e.g. evaporation or condensation
C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids
The invention provides a composition comprising carbon dioxide (C02, R-744), difluoromethane (R-32) and trifluoroiodomethane (CF3I) and the use of such a composition as a working fluid in a heat transfer system, such as a refrigeration, heat pump or air-conditioning system.
According to the present invention, there is provided a composition carbon dioxide (CO2, R- 744), difluoromethane (R-32) and 1,1-difluoroethylene (R-1132a).
A method for at least partially draining an operating system, which contains a working fluid (comprising carbon dioxide (R744) and a halogenated hydrocarbon). The method comprises transferring the working fluid to a target container, from the operating system, wherein the working fluid is contacted with an absorptive bed.
F25B 45/00 - Arrangements for charging or discharging refrigerant
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01D 53/96 - Regeneration, reactivation or recycling of reactants
B01J 20/30 - Processes for preparing, regenerating or reactivating
F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point
9.
METHOD FOR CHARGING A CONTAINER FOR USE WITH A MEDICATION DELIVERY APPARATUS, CONTAINER FOR SUCH AN APPARATUS AND METHOD FOR TREATING A PATIENT
A method of charging a container for use in a medication delivery apparatus wherein the propellant used comprises 1,1-difluoroethane (R-152a) is described.
B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
B65B 31/04 - Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
B65D 83/14 - Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
10.
METHOD FOR PREPARING A PARTIALLY FLUORINATED ALCOHOL
A method for preparing a partially fluorinated alcohol, comprises reacting an epoxide: wherein R1, R2, R3 and R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl with a fluorinating agent.
According to the present invention, there is provided a composition comprising 1,1- difluoroethylene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf) and carbo dioxide (CO2, R-744). The invention also provides a composition R-1132a, R-32, R-1234yf and at least one compound selected from the group consisting of: pentafluoroethane (R-125), 1,1-difluoroethane (R-152a), 1,1,1,2-tetrafluoroethane (R-134a), trans-1,3,3,3-tetrafluoropropene (R-1234ze(E)) and 1,1,1,2,3,3,3-heptafluoropropane (R-227ea); optionally, the composition comprises at least one further compound selected from the group consisting of trifluoroethylene (R-1123), propane (R-290), propylene (R-1270), isobutane (R-600a) and carbon dioxide (CO2, R-744). The present invention also provides a composition comprising R-1132a, R-32 and R-1234yf.
The invention provides a composition comprising (a) from about 6 to about 18 weight % R-1132a, (b) from about 5 to about 35 weight % R-32, and (c) from about 47 to about 89 weight % R-1234yf. The use of such a composition as a working fluid in a heat pump system of a vehicle, preferably an electric vehicle, is also provided.
C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
F25B 1/00 - Compression machines, plants or systems with non-reversible cycle
C08J 9/14 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
A composition comprising trifluoroiodomethane (CF3I) and 1,1-difluoroethylene (R-1132a) is described. The composition can also comprise additional compounds, such as at least one non-flammable compound selected from the group consisting of carbon dioxide (CO2; R-744), tetrafluoromethane (R-14), trifluoromethane (R-23) and perfluoroethane (R-116) or at least one additional compound of lower volatility than 1,1-difluoroethylene selected from the group consisting of 1, 1,2-trifluoroethylene (R-1123), difluoromethane (R-32), propane (R-290), propylene (R-1270), fluoroethane (R-161), pentafluoroethane (R-125), 1, 1,1,2- tetrafluoroethane (R-134a), 2,3,3,3-tetrafluopropene (R-1234yf), isobutane (R-600a), n-butane (R-600), trans-1,3,3,3-tetrafluopropene (R-1234ze(E)), 3,3,3-trifluoropropene (R-1243zf), 1,2,3,3,3-pentafluoropropene (R-1225ye), 1, 1,1,2,3,3,3-heptafluoropropane (R-227ea), 1,1- difluoroethane (R-152a), cis-1,3,3,3-tetrafluopropene (R-1234ze(Z)), 1-chloro-3,3,3- trifluoropropene (R-1233zd(E/Z)) and 1,1,1,4,4,4-hexafluoro-2-butene (R-1336mzz(E/Z)). The compositions have utility as refrigerants in vapour compression heat transfer systems.
A refrigerant composition comprising carbon dioxide (CO2; R-744) and from 1 to 32 weight % difluoromethane (R-32) based on the total weight of the composition is described. Also described is the use of the refrigerant composition for providing heating and cooling and a refrigeration, air-conditioning or heat pump system comprising the refrigerant composition.
Use as a refrigerant in a heat pump system in an electric vehicle of a composition is described. The composition comprises 1,1-difluoroethylene (R-1132a) and at least one fluorocarbon refrigerant compound selected from the group consisting of 2,3,3,3-tetrafluoropropene (R- 1234yf), difluoromethane (R-32), 1,3,3,3-tetrafluoropropene (R-1234ze(E)) and 1,1- difluoroethane (R-152a).
A pharmaceutical composition is described. The composition comprises; (i) a drug component comprising salbutamol; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
A composition comprising: (i) 1,1-difluoroethene (vinylidene fluoride, R-1132a); (ii) carbon dioxide (CO2, R-744); (iii) pentafluoroethane (R-125); and (iv) one or more of trifluoromethane (R-23) and hexafluoroethane (R-116).
In the field of medical dosing device filling, a propellant conditioning assembly (10) comprises an input conduit (12) to receive a propellant at a constant pressure from a propellant reservoir (102). The conditioning assembly (10) also includes a bifurcation (18) to divide the input conduit (12) into first and second conditioning conduits (20, 22). The first conditioning conduit (20) includes a cooler device (24) to selectively cool a diverted first propellant stream (26) that flows through the first conditioning conduit (20), and the second conditioning conduit (22) includes a heater device (32) to selectively heat a diverted second propellant stream (34) that flows through the second conditioning conduit (22). The conditioning assembly (10) still further includes an output conduit (44) to receive the first and second propellant streams (26, 34). The relative proportion of the first and second propellant streams (26, 34) merging in the output conduit (44) is controlled to regulate the temperature of a merged constant pressure propellant feed (46) exiting from the output conduit (44).
A propellant filling apparatus (10) comprising a filling booth (11) for receiving within it one or more containers for filling with a propellant; a propellant inlet (12) to the filling booth (11) that is capable of supplying propellant into one or more containers within the filling booth (11) from a propellant supply; an inert gas inlet (13) supplying inert gas from an inert gas supply (14) into the filling booth (11), a discharge outlet (16) from the filling booth (11); an extraction fan (17) that is capable of adjusting its fan speed to maintain the pressure of gas in the filling booth (11) to be lower than atmospheric pressure; and an oxygen detector (27) that is capable of detecting levels of oxygen in the filling booth (11) and triggering circulation of inert gas in the filling booth (11) when the level of oxygen in the filling booth (11) falls below an oxygen threshold level.
A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one tiotropium compound selected from tiotropium and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 11/00 - Drugs for disorders of the respiratory system
22.
STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING GLYCOPYRROLATE AND 1,1-DIFLUOROETHANE (HFA-152A) SUITABLE FOR USE IN METERED DOSE INHALERS (MDIS)
A pharmaceutical composition is described. The difficulty to formulate glycopyrrolate in a form that is suitable for delivery using metered dose inhaler is overcome by using a propellant that comprises 1,1-difluoroethane (HFA-152a) which improves chemical stability of the composition. Accordingly, the composition comprises: (i) a drug component comprising at least one pharmaceutically acceptable salt of glycopyrrolate; and (ii) a propellant component comprising HFA-152a.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 9/00 - Medicinal preparations characterised by special physical form
ABSTRACT A pharmaceutical composition is described. The difficulty to formulate indacaterol in a form that is suitable for delivery using metered dose inhaler is overcome by using a propellant that comprises 1,1-difluoroethane (HFA-152a) which improves chemical stability of the composition. Accordingly, the composition comprises: (i) a drug component comprising at least one indacaterol compound selected from indacaterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1- difluoroethane (HFA-152a). Date Recue/Date Received 2020-10-05
Abstract A pharmaceutical composition is described. The difficulty to formulate salmeterol in a form that is suitable for delivery using metered dose inhaler is overcome by using a propellant that comprises 1,1-difluoroethane (HFA-152a) which improves chemical stability of the composition. Accordingly, the composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a). Date Recue/Date Received 2020-10-05
A pharmaceutical composition is described. The composition comprises:(i) a drug component comprising at least one beclomethasone compound selected from beclomethasone and the pharmaceutically acceptable derivatives thereof and at least one long acting beta-2-agonist; (ii) a propellant component comprising 1,1- difluoroethane (HFA-152a); and (iii) glycerol.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1- difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.
A pharmaceutical composition is described. The composition comprises: (i) at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol; (ii) at least one corticosteroid; (iii) a surfactant component comprising at least one surfactant compound; and (iv) a propellant component comprising 1,1 - difluoroethane (R-152a).
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
28.
PROCESS FOR PURIFYING (HYDRO)FLUOROPROPENES CONTAMINATED WITH HALOGENATED ETHANE
A process for treating a composition comprising one or more desired (hydro)fluoroolefins and one or more undesired halogenated ethanes, halogenated methanes or mixtures thereof so as to reduce the concentration of at least one undesired halogenated ethane or halogenated methane, the process comprising contacting the composition with an adsorbent comprising pores having openings which have a size across their largest dimension of about 6 A or less.
B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
C07C 17/389 - Separation; Purification; Stabilisation; Use of additives by adsorption on solids
patents
